Stock News

Analysts See $0.19 EPS for Corcept Therapeutics (CORT); First Foundation Advisors Upped By $780,000 Its Grubhub (GRUB) Position

First Foundation Advisors increased Grubhub Inc (GRUB) stake by 59.58% reported in 2017Q3 SEC filing. First Foundation Advisors acquired 15,000 shares as Grubhub Inc (GRUB)’s stock rose 15.35%. The First Foundation Advisors holds 40,178 shares with $2.12M value, up from 25,178 last quarter. Grubhub Inc now has $7.73 billion valuation. The stock increased 1.29% or $1.1333 during the last trading session, reaching $89.1033. About 609,802 shares traded. GrubHub Inc. (NYSE:GRUB) has risen 94.22% since February 14, 2017 and is uptrending. It has outperformed by 77.52% the S&P500.

Analysts expect Corcept Therapeutics Incorporated (NASDAQ:CORT) to report $0.19 EPS on March, 5.They anticipate $0.15 EPS change or 375.00% from last quarter’s $0.04 EPS. CORT’s profit would be $21.69 million giving it 20.38 P/E if the $0.19 EPS is correct. After having $0.11 EPS previously, Corcept Therapeutics Incorporated’s analysts see 72.73% EPS growth. The stock increased 3.75% or $0.56 during the last trading session, reaching $15.49. About 239,908 shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 124.81% since February 14, 2017 and is uptrending. It has outperformed by 108.11% the S&P500.

Investors sentiment decreased to 1.96 in Q3 2017. Its down 0.47, from 2.43 in 2017Q2. It worsened, as 13 investors sold Corcept Therapeutics Incorporated shares while 39 reduced holdings. 47 funds opened positions while 55 raised stakes. 71.96 million shares or 6.38% more from 67.64 million shares in 2017Q2 were reported. Pnc Fin Serv Gp stated it has 305,179 shares. Cambridge holds 0.05% or 40,000 shares. Numeric Invsts Ltd Com holds 0.05% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 361,413 shares. Zebra Mngmt Ltd Liability Corporation holds 33,891 shares or 0.21% of its portfolio. Vanguard Group has 6.24M shares. Great West Life Assurance Can holds 7,612 shares. Renaissance Ltd Liability Corporation invested 0.08% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Swiss Bancorporation holds 0% or 138,700 shares in its portfolio. Meeder Asset Incorporated reported 886 shares stake. Blume Capital Management Inc has 0.01% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 700 shares. Barclays Public Ltd Com reported 86,475 shares stake. Gsa Capital Ptnrs Ltd Liability Partnership, United Kingdom-based fund reported 151,282 shares. Prudential Finance Inc reported 1.10M shares. Shaker Invs Ltd Oh owns 114,085 shares or 1.53% of their US portfolio. Sanctuary Wealth Limited Company, California-based fund reported 465 shares.

Since December 8, 2017, it had 0 buys, and 3 selling transactions for $415,899 activity. FISHMAN ROBERT S had sold 8,000 shares worth $133,776 on Friday, December 8.

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics had 7 analyst reports since February 2, 2017 according to SRatingsIntel. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by Piper Jaffray on Wednesday, October 11. On Friday, November 3 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Buy” rating given on Thursday, February 2 by Ladenburg Thalmann. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Friday, September 8 with “Buy” rating. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) rating on Thursday, August 24. Piper Jaffray has “Buy” rating and $18.0 target.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $1.77 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 53.41 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

Among 32 analysts covering Grubhub Inc (NYSE:GRUB), 19 have Buy rating, 3 Sell and 10 Hold. Therefore 59% are positive. Grubhub Inc had 120 analyst reports since July 27, 2015 according to SRatingsIntel. Oppenheimer maintained GrubHub Inc. (NYSE:GRUB) on Wednesday, July 29 with “Outperform” rating. The firm earned “Buy” rating on Tuesday, September 5 by Bank of America. The company was downgraded on Monday, June 26 by Morgan Stanley. Northland Capital maintained GrubHub Inc. (NYSE:GRUB) rating on Wednesday, October 28. Northland Capital has “Outperform” rating and $30 target. Roth Capital maintained the shares of GRUB in report on Monday, July 31 with “Buy” rating. On Friday, February 9 the stock rating was maintained by Susquehanna with “Hold”. The firm has “Outperform” rating by Oppenheimer given on Wednesday, April 12. The stock of GrubHub Inc. (NYSE:GRUB) earned “Hold” rating by Raymond James on Monday, February 5. The company was maintained on Thursday, January 4 by Credit Suisse. The company was maintained on Thursday, October 26 by Morgan Stanley.

Leave a Reply

Your email address will not be published. Required fields are marked *